Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sutro Biopharma Inc (STRO)

Sutro Biopharma Inc (STRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 73,727
  • Shares Outstanding, K 8,514
  • Annual Sales, $ 62,040 K
  • Annual Income, $ -227,460 K
  • EBIT $ -186 M
  • EBITDA $ -188 M
  • 60-Month Beta 1.61
  • Price/Sales 1.29
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 185.62% (-12.54%)
  • Historical Volatility 115.94%
  • IV Percentile 16%
  • IV Rank 7.75%
  • IV High 1,186.13% on 11/04/25
  • IV Low 101.57% on 01/21/25
  • Expected Move (DTE 12) 0.64 (7.36%)
  • Put/Call Vol Ratio 1.59
  • Today's Volume 88
  • Volume Avg (30-Day) 37
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 1,303
  • Open Int (30-Day) 2,706
  • Expected Range 8.02 to 9.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -4.45
  • Number of Estimates 7
  • High Estimate -3.98
  • Low Estimate -4.90
  • Prior Year -8.90
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.15 +21.12%
on 12/03/25
9.97 -13.10%
on 11/14/25
-1.14 (-11.63%)
since 11/05/25
3-Month
7.15 +21.12%
on 12/03/25
13.10 -33.89%
on 10/21/25
-1.94 (-18.30%)
since 09/05/25
52-Week
5.23 +65.55%
on 04/17/25
30.10 -71.23%
on 12/09/24
-19.14 (-68.85%)
since 12/05/24

Most Recent Stories

More News
Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors

– Initial clinical data expected mid-2026 – SOUTH SAN FRANCISCO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology...

STRO : 8.66 (-7.68%)
Sutro Biopharma Announces 1-for-10 Reverse Stock Split

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format...

STRO : 8.66 (-7.68%)
Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day

- Company has initiated Phase 1 study with STRO-004, its potential best-in-class Tissue Factor ADC -  - Sutro has selected PTK7 as the target for its initial dual-payload candidate, STRO-227 - ...

STRO : 8.66 (-7.68%)
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights

– Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC; Expects to dose first patient before year-end – ...

STRO : 8.66 (-7.68%)
Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug...

STRO : 8.66 (-7.68%)
Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug...

STRO : 8.66 (-7.68%)
Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones

– Extends cash runway into at least mid-2027 – SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company...

STRO : 8.66 (-7.68%)
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone

USA News Group News Commentary

ONCY : 0.9921 (+1.16%)
AGEN : 3.93 (-3.20%)
CSTL : 38.64 (-2.47%)
STRO : 8.66 (-7.68%)
IBRX : 2.29 (-0.43%)
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone

/CNW/ -- Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with...

ONCY : 0.9921 (+1.16%)
AGEN : 3.93 (-3.20%)
CSTL : 38.64 (-2.47%)
STRO : 8.66 (-7.68%)
IBRX : 2.29 (-0.43%)
Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates

SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug...

STRO : 8.66 (-7.68%)

Business Summary

Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in...

See More

Key Turning Points

3rd Resistance Point 9.87
2nd Resistance Point 9.55
1st Resistance Point 9.11
Last Price 8.66
1st Support Level 8.35
2nd Support Level 8.03
3rd Support Level 7.59

See More

52-Week High 30.10
Fibonacci 61.8% 20.60
Fibonacci 50% 17.67
Fibonacci 38.2% 14.73
Last Price 8.66
52-Week Low 5.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar